{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:30Z","timestamp":1793946510577,"version":"4.8.0"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jns.2026.125857","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:58:55Z","timestamp":1773125935000},"page":"125857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on \u201cCSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen\u201d"],"prefix":"10.1016","volume":"485","author":[{"given":"Sadhana U.","family":"Adhyapak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek Kumar","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.V.","family":"Prasad Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125857_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2026.125795","article-title":"CSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen","volume":"482","author":"Pronto-Laborinho","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125857_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/mus.28476","article-title":"Evaluating the effects of nusinersen treatment in adults with spinal muscular atrophy using axonal excitability and MscanFit MUNE","author":"Alaamel","year":"2025","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2026.125857_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf275","article-title":"CSF and blood neuronal injury biomarkers in spinal bulbar muscular atrophy and amyotrophic lateral sclerosis 4","volume":"7","author":"Shahim","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.jns.2026.125857_bb0020","first-page":"79","article-title":"Latest experimental data on the role of VEGF in the treatment of spinal cord injury","volume":"7","author":"Katsamoundis","year":"2025","journal-title":"Eur. J. Med. Health Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:52:20Z","timestamp":1793944340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":4,"alternative-id":["S0022510X26001395"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125857","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cCSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125856","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125857"}}